Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease

Diabetologia

Volumn 43, Issue 10, 2000, Pages 1205-1223

  Flyvbjerg, A ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Angiotensin converting enzyme inhibition; Antagonist; Epidermal growth factor; Growth hormone; Insulin like growth factors; Nephropathy; Protein kinase C inhibition; Somatostatin analogue; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOPEPTIN; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; MESSENGER RNA; OCTREOTIDE; PLACEBO; PROTEIN KINASE C INHIBITOR; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; HUMAN; HYPERTENSION; KIDNEY CELL; KIDNEY DISEASE; KIDNEY FUNCTION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; CYTOKINES; DIABETIC NEPHROPATHIES; ENDOTHELIAL GROWTH FACTORS; EPIDERMAL GROWTH FACTOR; GROWTH HORMONE; GROWTH SUBSTANCES; HUMANS; LYMPHOKINES; SOMATOMEDINS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033789935     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051515     Document Type: Article

References (170)

1. Prognosis of diabetics with diabetes onset before age thirty one
2. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus
3. Predicting diabetic nephropathy in insulin dependent diabetes mellitus
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
6. Permanent diabetes produced by pituitary (anterior lobe) injections
7. The production of permanent diabetes by highly purified growth hormone
8. Abnormal growth hormone response to ingestion of glucose in juvenile diabetics
9. Diurnal pattern of blood glucose, serum FFA, insulin, glucagon and growth hormone in normals and juvenile diabetics
10. Diabetes, diabetic angiopathy and growth hormone (hypothesis)
11. The growth hormone dependent sulphation factor in serum from patients with various types of diabetes
12. Growth factors and diabetic complications
13. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy
14. Expression of the growth hormone binding protein messenger RNA in the liver and extra-hepatic tissues in the rat; co-expression with the growth hormone receptor
15. Differential expression of renal growth hormone receptor and its binding protein in experimental diabetes mellitus
16. Distinct receptors for insulin-like growth factor I in rat renal glomeruli and tubules
17. Experimental diabetes increases insulin-like growth factor I and II receptor concentration and gene expression in kidney
18. Luminal and basolateral uptake and receptor binding of IGF-I in rabbit renal proximal tubules
19. Identification of five different IGFBPs from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human
20. Isolation and molecular cloning of IGFBP-6
21. The insulin-like growth factor binding protein (IGFBP) superfamily
22. Focal expression of insulin-like growth factor I in rat kidney collecting duct
23. Kidney IGF-I mRNA in initial renal hypertrophy in experimental diabetes in rats
24. Tissue distribution of insulin-like growth factor I and II ribonucleic acid in the adult rat
25. Expression of insulin-like growth factor binding proteins in the rat kidney: Effects of long-term diabetes
26. International symposium on glucose metabolism and growth factors
27. Studies on binding and mitogenic effect of insulin and insulin-like growth factor I in glomerular mesangial cells
28. Insulin-like growth factor I is a progression factor for human mesangial cells
29. Effects of IGF-I and glucose on protein and proteoglycan synthesis by human fetal mesangial cells in culture
30. Stimulation of proteoglycan by IGF-I and -II in microvessel and large vessel endothelial cells
31. Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factor I
32. IGF-I decreases collagen degradation in diabetic NOD mesangial cells: Implications for diabetic nephropathy
33. Growth hormone secretion dynamics in streptozotocin diabetes: Evidence of a role for endogenous somatostatin
34. Alterations in the growth hormone/insulin-like growth factor axis in human and experimental diabetes: Differences and similarities
35. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy and urinary albumin excretion in experimental diabetes in mice
36. Normalization of decreased plasma concentrations of growth hormone-binding protein by insulin treatment in spontaneously diabetic BB rats
37. Low plasma somatomedin-C in streptozotocin-induced diabetes mellitus. Correlation with changes in somatogenic and lactogenic liver binding sites
38. The role of insulin-like growth factor I in intial renal hypertrophy in experimental diabetes
39. Regulation of insulin-like growth factor I and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues
40. Kidney IGF-I and renal hypertrophy in GH deficient dwarf rats
41. Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomized rats
42. Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats
43. Effect of puberty on initial kidney growth and rise in kidney IGF-I in diabetic rats
44. Focal induction of IGF-binding proteins in the proximal tubules of diabetic rat kidney
45. Kidney tissue insulin-like growth factor I and initial renal growth in diabetic rats: Relation to severity of diabetes
46. Renal hypertrophy in hyperglycemic nonobese diabetic (NOD) mice is associated with persistent renal accumulation of insulin-like growth factor (IGF) I
47. Effect of insulin-like growth factor I infusion on renal hypertrophy in experimental diabetes mellitus in rats
48. Growth hormone-deficient dwarfism in the rat: A new mutation
49. Effect of isolated GH and IGF-I deficiency on long-term renal changes and urinary albumin excretion in streptozotocin diabetic dwarf rats
50. Kidney insulin-like growth factor I mRNA levels are increased in postpubertal diabetic rats
51. Insulin-like growth factor I (IGF-I) and IGF-I receptor gene expression in the kidney of chronically hypoinsulinemic rat and hyperinsulinemic rat
52. Renal insulin-like growth factor I and growth hormone receptor binding in experimental diabetes and after unilateral nephrectomy in the rat
53. Increased kidney and liver insulin-like growth factor II/Mannose-6-phosphate receptor concentration in experimental diabetes in rats
54. Transient increase in renal IGF binding proteins during initial kidney hypertrophy in experimental diabetes in rats
55. Effect of lanreotide, a somatostatin analogue, on diabetic renal hypertrophy, kidney and serum IGF-I and IGF binding proteins
56. The effect of a somatostatin analogue (SMS201-995) on the concentration of phosphoribosyl pyrophosphate and the activity of the pentose phosphate pathway in the early renal hypertrophy of experimental diabetes in the rat
57. Effect of octreotide on experimental diabetic renal and glomerular growth: Importance of early intervention
58. Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats
59. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats
60. Stimulation of hepatic insulin-like growth factor binding protein-1 and -3 gene expression by octreotide in rats
61. Octreotide administration in diabetic rats: Effects on renal hypertrophy and urinary albumin excretion
62. Long-term effects of a somatostatin analogue on renal haemodynamics and hypertrophy in diabetic rats
63. Effect of a somatostatin analogue (SMS 201-995) on urinary albumin excretion in streptozotocin-induced diabetic rats
64. Effect of a somatostatin analogue (SMS 201-995) on renal function and excretion in diabetic rats
65. Effect of octreotide, captopril, or insulin on manifest long-term experimental diabetic renal changes
66. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice
67. Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice
68. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice
69. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin
70. Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice
71. Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice
72. Effect of growth hormone (GH) receptor antagonist (G120K-PEG) treatment on manifest renal changes in non obese diabetic (NOD) mice
73. Inhibition of cell proliferation by peptide analogues of insulin-like growth factor I
74. Stable D-peptide analogue of insulin-like growth factor I inhibits smooth muscle cell proliferation after carotid balloning injury in the rat
75. JB3, an IGF-I receptor antagonist, inhibits early renal growth in diabetic and uninephrectomized rats
76. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor I receptor
77. Insulin-like growth factor I activates nuclear factor-κB and increases transcription of the intercellular adhesion molecule-1 gene in endothelial cells
78. Vascular endothelial growth factor activates nuclear factor-κB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells
79. Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy
80. Renal enlargement and IGF-I accumulation in experimental diabetes is not prevented by angiotensin converting enzyme inhibition
81. Transforming growth factor β: An overview
82. Mechanism of activation of the TGF-β receptor
83. mRNA expression of growth factors in glomeruli from diabetic rats
84. Self limited stimulation of mesangial cell growth in high glucose: Autocrine activation of TGF-β reduces proliferation but increases mesangial matrix
85. Rat mesangial cell hypertrophy, in response to transforming growth factor β1
86. The renal expression of transforming growth factor β isoforms and their receptors in acute and chronic experimental diabetes in rats
87. High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule
88. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor β1
89. Role of protoglycans and cytoskeleton in the effects of TGF-β1 on renal proximal tubule cells
90. TGF-β1: Regulation of extracellular matrix
91. The purification and characterisation of a glomerular basement membrane degrading neutral proteinase from the rat mesangial cells
92. Transforming growth factor β1 stimulates mesangial cell synthesis of the 72 kD type IV collagenase
93. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial matrix
94. High glucose-induced TGF-β1 regulates mesangial production of heparan sulphate proteoglycan
95. Expression of transforming growth factor β1 during diabetic renal hypertrophy
96. Renal hypertrophy is associated with upregulation of TGF-β1 gene expression in diabetic BB rat and NOD mouse
97. Renal TGF-β regulation in spontaneously diabetic NOD mice with correlations in mesangial cells
98. Under control of the Ren-1 c promoter, locally produced transforming growth factor-β1 induces accumulation of glomerular extracellular matrix in transgenic mice
99. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor β
100. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice
101. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells
102. 1 cells partly by decreasing transforming growth factor-β receptor protein expression
103. Expression of transforming growth factor β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of angiotensin converting enzyme inhibition
104. Effect of ACE-inhibition on renal TGF-β type II receptor expression in experimental diabetes in rats
105. Protein kinase C activation and the development of diabetic complications
106. Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-β in mesangial cells
107. Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions
108. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats
109. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor
110. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes
111. Effect of protein kinase C β inhibition on renal morphology, urinary albumin excretion and renal transforming growth factor β in experimental diabetes in rats
112. Suppression of transforming growth factor β and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195
113. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
114. Vascular permeability factor, an endothelial cell mitogen related to PDGF
115. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
116. Vascular endothelial growth factor (VEGF) and its receptors
117. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor
118. Vascular endothelial growth factor is a secreted angiogenic mitogen
119. Vascular endothelial growth factor is a potential tumour angiogenesis factor in humans gliomas in vivo
120. The vascular endothelial growth factor family of polypeptides
121. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
122. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
123. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
124. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
125. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues
126. Vascular permeability factor mRNA and protein expression in human kidney
127. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney
128. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts
129. 125I]VEGF binding sites
130. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes
131. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy ?
132. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells
133. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by mesangial cells
134. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells
135. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells
136. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human smooth miscle cells in vitro
137. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor
138. The von Hippel-Lindau gene products inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways
139. Transforming growth factor β1 downregulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells
140. Vascular endothelial growth factor is induced in response to transforming growth factor β in fibroblastic and epithelial cells
141. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I
142. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: Synergistic interaction with hypoxia
143. Serum and platelet-derived growth factor-induced expression of vascular permeability factor mRNA by human vascular smooth muscle cells in vitro
144. Vascular endothelial growth factor and diabetes: The agonist versus antagoninst paradox
145. Hyperfiltration and albuminuria in diabetes: Role of vascular endothelial growth factor (VEGF)
146. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor
147. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor
148. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY 333 531
149. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
150. The type 1 (EGFR-related) family of growth factor receptors and their ligands
151. Epidermal growth factor related peptides and their receptors in human malignancies
152. Renal origin of rat urinary epidermal growth factor
153. Cellular localization of human epidermal growth factor receptor
154. Evidence for glomerular actions of epidermal growth factor in the rat
155. Effect of epidermal growth factor on sodium transport in the cortical collecting tubule
156. High affinity binding sites for epidermal growth factor (EGF) in renal membranes
157. Epidermal growth factor binding, stimulation of phosphorylation, and inhibition of glyconeogenesis in rat proximal tubule
158. Epidermal growth factor and the kidney
159. EGF-induced mitogenesis in proximal tubular cells: Potentiation by angiotensin II
160. In vivo cardiovascular, renal and endocrine effects of epidermal growth factor in sheep
161. Epidermal growth factor rapidly activates the hexose monophosphate shunt in kidney cells
162. Effect of epidermal growth factor on sodium transport in the cortical collecting tubules
163. Urinary excretion of epidermal growth factor in living human kidney doners and their recipients
164. Epidermal growth factor is expressed by cells in the distal tubulus during postnephrectomy renal growth
165. Epidermal growth factor in renal hypertrophy in streptozotocin-diabetic rats
166. Increased epidermal growth factor in experimental diabetes related renal growth
167. Urinary excretion of epidermal growth factor and Tamm-Horsfall protein in three rat models with increased renal excretion of urine
168. Adrenergic blockade in diabetic and uninephrectiomized rats: Effects on renal size and on renal and urinary contents of epidermal growth factor